[go: up one dir, main page]

MX2020004074A - Producto de combinacion para el tratamiento de cancer. - Google Patents

Producto de combinacion para el tratamiento de cancer.

Info

Publication number
MX2020004074A
MX2020004074A MX2020004074A MX2020004074A MX2020004074A MX 2020004074 A MX2020004074 A MX 2020004074A MX 2020004074 A MX2020004074 A MX 2020004074A MX 2020004074 A MX2020004074 A MX 2020004074A MX 2020004074 A MX2020004074 A MX 2020004074A
Authority
MX
Mexico
Prior art keywords
cancer
treatment
combination product
effective amount
therapeutically effective
Prior art date
Application number
MX2020004074A
Other languages
English (en)
Inventor
Grégoire Vuagniaux
Norbert Wiedemann
Claudio Zanna
Original Assignee
Debiopharm Int Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debiopharm Int Sa filed Critical Debiopharm Int Sa
Publication of MX2020004074A publication Critical patent/MX2020004074A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Endocrinology (AREA)

Abstract

Se proveen métodos para administrar una cantidad terapéuticamente efectiva de Debio 1143 y una cantidad terapéuticamente efectiva de un anticuerpo anti-PD-L1 o fragmento de unión a antígeno del mismo, para el tratamiento de cáncer.
MX2020004074A 2017-10-19 2018-10-19 Producto de combinacion para el tratamiento de cancer. MX2020004074A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762574384P 2017-10-19 2017-10-19
EP18191980 2018-08-31
PCT/EP2018/078763 WO2019077132A1 (en) 2017-10-19 2018-10-19 COMBINATION PRODUCT FOR THE TREATMENT OF CANCER

Publications (1)

Publication Number Publication Date
MX2020004074A true MX2020004074A (es) 2020-10-16

Family

ID=63915057

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004074A MX2020004074A (es) 2017-10-19 2018-10-19 Producto de combinacion para el tratamiento de cancer.

Country Status (12)

Country Link
US (2) US20210198365A1 (es)
EP (1) EP3697816A1 (es)
JP (2) JP7422070B2 (es)
KR (1) KR20200072507A (es)
CN (1) CN111655725A (es)
AU (1) AU2018353432A1 (es)
BR (1) BR112020007046A2 (es)
CA (1) CA3078155A1 (es)
IL (1) IL273835A (es)
MX (1) MX2020004074A (es)
SG (1) SG11202003486UA (es)
WO (1) WO2019077132A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3558363A1 (en) 2016-12-21 2019-10-30 Amgen Inc. Anti-tnf alpha antibody formulations
BR112020007046A2 (pt) * 2017-10-19 2020-11-17 Debiopharm International S.A. produto de combinação para o tratamento do câncer
EP3911316A1 (en) 2019-01-17 2021-11-24 Debiopharm International SA Combination product for the treatment of cancer

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
CA1340288C (en) 1988-09-02 1998-12-29 Robert Charles Ladner Generation and selection of novel binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2090473A1 (en) 1990-08-29 1992-03-01 Robert M. Kay Homologous recombinatin in mammalian cells
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
WO1992015677A1 (en) 1991-03-01 1992-09-17 Protein Engineering Corporation Process for the development of binding mini-proteins
ATE269401T1 (de) 1991-04-10 2004-07-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
EP1589107B1 (en) 1992-08-21 2009-12-23 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
HRP20151102T1 (xx) 2005-07-01 2015-11-20 E. R. Squibb & Sons, L.L.C. Humana monoklonska antitijela za ligand programirane smrti 1 (pd-l1)
WO2008128171A2 (en) 2007-04-13 2008-10-23 The Regents Of The University Of Michigan Diazo bicyclic smac mimetics and the uses thereof
JP6087503B2 (ja) 2008-09-26 2017-03-08 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ヒト抗ｐｄ−１、ｐｄ−ｌ１、及びｐｄ−ｌ２抗体とその用途
SMT202500126T1 (it) 2008-12-09 2025-05-12 Hoffmann La Roche Anticorpi anti-pd-l1 e loro uso per potenziare la funzione dei linfociti t
ES2629337T3 (es) 2009-02-09 2017-08-08 Inserm - Institut National De La Santé Et De La Recherche Médicale Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione
HRP20171653T1 (hr) 2009-11-24 2017-12-15 Medimmune Limited Vezna sredstva koja služe ciljano protiv b7-h1
BR112014002353B1 (pt) 2011-08-01 2022-09-27 Genentech, Inc Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit
US9624298B2 (en) 2011-11-28 2017-04-18 Merck Patent Gmbh Anti-PD-L1 antibodies and uses thereof
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
AU2014339900B2 (en) 2013-10-25 2019-10-24 Dana-Farber Cancer Institute, Inc. Anti-PD-L1 monoclonal antibodies and fragments thereof
CA2963281A1 (en) 2014-10-03 2016-04-07 Novartis Ag Combination therapies
US20210322545A1 (en) * 2016-02-24 2021-10-21 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
KR20190130644A (ko) * 2017-03-31 2019-11-22 베링거 인겔하임 인터내셔날 게엠베하 항암 조합 요법
BR112020007046A2 (pt) * 2017-10-19 2020-11-17 Debiopharm International S.A. produto de combinação para o tratamento do câncer

Also Published As

Publication number Publication date
AU2018353432A1 (en) 2020-04-23
US20210198365A1 (en) 2021-07-01
SG11202003486UA (en) 2020-05-28
EP3697816A1 (en) 2020-08-26
CA3078155A1 (en) 2019-04-25
JP2021500320A (ja) 2021-01-07
JP2024054123A (ja) 2024-04-16
JP7422070B2 (ja) 2024-01-25
IL273835A (en) 2020-05-31
KR20200072507A (ko) 2020-06-22
WO2019077132A1 (en) 2019-04-25
BR112020007046A2 (pt) 2020-11-17
CN111655725A (zh) 2020-09-11
US20240010731A1 (en) 2024-01-11

Similar Documents

Publication Publication Date Title
CL2020003071A1 (es) Proteínas de unión multiespecíficas y mejoras con estas
CL2022001189A1 (es) Anticuerpos para cd40. (divisional de solicitud n° 2017003427)
MX2021013788A (es) Dosificación del inhibidor de kras para el tratamiento de cánceres.
CY1122642T1 (el) Αντι-β7-η1 και anti-ctla-4 αντισωματα για τη θεραπευτικη αγωγη μη μικροκυτταρικου πνευμονικου καρκινου
CL2019001411A1 (es) Métodos para inhibición de la fibrosis en un sujeto en necesidad de ellos. (divisional solicitud 201801817)
CY1125205T1 (el) Φαρμακευτικες συνθεσεις δραστικων απο θεραπευτικη αποψη ενωσεων
MX2019009772A (es) Anticuerpos anti-pd-1 para el tratamiento del cancer de pulmon.
MX2018008514A (es) Composiciones y metodos relacionados con sistemas celulares terapeuticos multimodales para indicaciones cancerosas.
MX373045B (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
MX2018008995A (es) Combinacion de un agonista de ox40 y un agonista de 4-1bb para tratar el cancer.
MX2018005720A (es) Anticuerpos pd-l1, fragmento de union al antigeno del mismo, y aplicacion medica de ello.
CU24498B1 (es) Anticuerpos de factor xi
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
CO2022009696A2 (es) Anticuerpo anti-lilrb1 y usos del mismo
CL2017002983A1 (es) Terapia combinada de un anticuerpo anti-cd-20 con un inhibidor de bcl-2 y un inhibidor de mdm2
EA201792300A1 (ru) Комбинации иммуноконъюгата к cd37 и антитела к cd20
MX2020007406A (es) Anticuerpo pd-l1, fragmento de union al antigeno del mismo y uso farmaceutico del mismo.
FI3773689T3 (fi) Antigeenisiä peptidejä syövän ehkäisyyn ja hoitoon
DOP2021000130A (es) Moduladores de la expresion de hsd17b13
EP4603508A3 (en) Anti-frizzled antibodies and methods of use
MX2017007595A (es) Inmunoterapia para enfermedad angiogenica.
EA201991818A1 (ru) Лечение рака
MX2017001686A (es) Anticuerpos anti-ceramida.
MX2023008849A (es) Terapia combinada mediante el uso de un conjugado de anticuerpo-farmaco de liv1 (liv1-adc) y agente quimioterapeutico.
WO2018089807A3 (en) Anti-cd46 antibodies and methods of use